Barclays Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its target price upped by Barclays from $98.00 to $103.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the medical device company’s stock.

Several other research firms have also weighed in on COO. William Blair upgraded Cooper Companies to a “strong-buy” rating in a report on Friday, January 30th. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, December 5th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Rothschild & Co Redburn lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Cooper Companies Stock Down 4.6%

Shares of Cooper Companies stock traded down $3.65 during midday trading on Friday, reaching $76.55. 5,297,517 shares of the company’s stock traded hands, compared to its average volume of 1,770,237. The company has a market cap of $14.94 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 2.29 and a beta of 1.02. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $89.83. The company’s 50 day simple moving average is $82.11 and its 200 day simple moving average is $75.97. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the business posted $0.92 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Equities analysts expect that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cooper Companies news, Director Lawrence Erik Kurzius purchased 2,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were bought at an average cost of $82.50 per share, with a total value of $165,000.00. Following the transaction, the director directly owned 7,777 shares in the company, valued at approximately $641,602.50. This represents a 34.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Maria Rivas acquired 1,000 shares of Cooper Companies stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, with a total value of $82,130.00. Following the completion of the transaction, the director directly owned 11,141 shares of the company’s stock, valued at $915,010.33. This trade represents a 9.86% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 16,014 shares of company stock worth $1,304,416. 2.08% of the stock is currently owned by company insiders.

Institutional Trading of Cooper Companies

A number of hedge funds have recently bought and sold shares of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Cooper Companies by 48.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after buying an additional 7,363 shares during the last quarter. Assetmark Inc. increased its stake in Cooper Companies by 357.8% during the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 483 shares during the period. Resona Asset Management Co. Ltd. raised its holdings in Cooper Companies by 7.9% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 67,988 shares of the medical device company’s stock valued at $4,838,000 after acquiring an additional 4,976 shares in the last quarter. Twin Capital Management Inc. lifted its position in shares of Cooper Companies by 4.8% in the 2nd quarter. Twin Capital Management Inc. now owns 8,074 shares of the medical device company’s stock worth $575,000 after acquiring an additional 372 shares during the period. Finally, Bastion Asset Management Inc. bought a new stake in shares of Cooper Companies in the 2nd quarter worth approximately $8,784,000. 24.39% of the stock is owned by institutional investors.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.